A large amount of interesting data in chronic lymphocytic leukaemia (CLL) were presented at ASH 2018. Alexander Egle reports on the results from the ALLIANCE trial studying ibrutinib alone or in combination, and several study results on CD19 CAR-T cell therapy.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.